ImmunoGen - IMGN Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

7 brokerages have issued 12-month price targets for ImmunoGen's shares. Their IMGN share price forecasts range from $5.00 to $22.00. On average, they predict the company's share price to reach $12.11 in the next year. This suggests a possible upside of 166.2% from the stock's current price.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN stock has decreased by 8.3% and is now trading at $4.55.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, October, 29th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $9.20 million for the quarter, compared to analysts' expectations of $19.03 million. ImmunoGen had a negative trailing twelve-month return on equity of 75.89% and a negative net margin of 210.33%. ImmunoGen's revenue was down 49.5% compared to the same quarter last year. During the same period last year, the business posted ($0.13) EPS.

ImmunoGen issued an update on its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $80.22 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional investors include Pinnacle Associates Ltd. (0.60%), Pinnacle Associates Ltd. (0.60%), UBS Group AG (0.43%), Fisher Asset Management LLC (0.39%), Swiss National Bank (0.22%) and Hennion & Walsh Asset Management Inc. (0.21%). Insiders that own company stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends.

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $4.55.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.00 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

The company employs 106 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.